4.6 Article

Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer's Disease

Journal

FRONTIERS IN NEUROSCIENCE
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2018.01045

Keywords

Alzheimer's disease; mild cognitive impairment; radiomics; image fusion; Cox model

Categories

Funding

  1. National Natural Science Foundation of China [61603236, 81671239, 81361120393, 81401135, 81771483]
  2. National Key Research and Development Program of China from Ministry of Science and Technology of China [2016YFC1306305, 2016YFC1306500]
  3. Shanghai Technology and Science Key Project in Healthcare [17441902100]
  4. Science and Technology Commission of Shanghai Municipality [17JC1401600]
  5. Open Project Funding of Human Phenome Institute, Fudan University [HUPIKF2018203]
  6. Sino-German Institute for Brain Molecular Imaging and Clinical Translation
  7. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]
  8. Department of Defense DODADNI [W81XWH-12-2-0012]
  9. National Institute of Aging
  10. National Institute of Biomedical Imaging and Bioengineering
  11. AbbVie
  12. Alzheimer's Association
  13. Alzheimer's Drug Discovery Foundation
  14. Araclon Biotech
  15. BioClinica, Inc.
  16. Biogen
  17. Bristol-Myers Squibb Company
  18. CereSpir, Inc.
  19. Eisai Inc.
  20. Elan Pharmaceuticals, Inc.
  21. Eli Lilly and Company
  22. EuroImmun
  23. F. Hoffmann-La Roche Ltd.
  24. Genentech, Inc.
  25. Fujirebio
  26. GE Healthcare
  27. IXICO Ltd.
  28. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  29. Johnson & Johnson Pharmaceutical Research & Development LLC.
  30. Lumosity
  31. Lundbeck
  32. Merck Co., Inc.
  33. Meso Scale Diagnostics, LLC.
  34. NeuroRx Research
  35. Neurotrack Technologies
  36. Novartis Pharmaceuticals Corporation
  37. Pfizer Inc.
  38. Piramal Imaging
  39. Servier
  40. Takeda Pharmaceutical Company
  41. Transition Therapeutics
  42. Canadian Institutes of Health Research

Ask authors/readers for more resources

Predicting progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD) is clinically important. In this study, we propose a dual-model radiomic analysis with multivariate Cox proportional hazards regression models to investigate promising risk factors associated with MCI conversion to AD. T1 structural magnetic resonance imaging (MRI) and F-18-Fluorodeoxyglucose (FDG) positron emission tomography (PET) data, from the AD Neuroimaging Initiative database, were collected from 131 patients with MCI who converted to AD within 3 years and 132 patients with MCI without conversion within 3 years. These subjects were randomly partition into 70% training dataset and 30% test dataset with multiple times. We fused MRI and PET images by wavelet method. In a subset of subjects, a group comparison was performed using a two-sample t-test to determine regions of interest (ROIs) associated with MCI conversion. 172 radiomic features from ROIs for each individual were established using a published radiomics tool. Finally, L1-penalized Cox model was constructed and Harrell's C index (C-index) was used to evaluate prediction accuracy of the model. To evaluate the efficacy of our proposed method, we used a same analysis framework to evaluate MRI and PET data separately. We constructed prognostic Cox models with: clinical data, MRI images, PET images, fused MRI/PET images, and clinical variables and fused MRI/PET images in combination. The experimental results showed that captured ROIs significantly associated with conversion to AD, such as gray matter atrophy in the bilateral hippocampus and hypometabolism in the temporoparietal cortex. Imaging model (MRI/PET/fused) provided significant enhancement in prediction of conversion compared to clinical models, especially the fused-modality Cox model. Moreover, the combination of fused-modality imaging and clinical variables resulted in the greatest accuracy of prediction. The average C-index for the clinical/MRI/PET/fused/combined model in the test dataset was 0.69, 0.73, 0.73 and 0.75, and 0.78, respectively. These results suggested that a combination of radiomic analysis and Cox model analyses could be used successfully in survival analysis and may be powerful tools for personalized precision medicine patients with potential to undergo conversion from MCI to AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available